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| BACKG ROU N D
The cardiovascular outcome trial EMPA-REG OUTCOME 1 showed that empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduces the relative risk of cardiovascular death by 38% (HR 0.62; 95% CI: 0.49-0.77), all-cause mortality by 32% (HR 0.68; 95% CI: 0.57-0.82) and hospitalization for heart failure by 35% (HR 0.65; 95% CI: 0.50-0.85) when added onto standard of care in patients with type 2 diabetes (T2D) and established cardiovascular disease.
However, the beneficial effects seen in the EMPA-REG OUTCOME trial are yet to be evaluated in routine clinical care, which includes patients across a broader spectrum of cardiovascular risk.
Moreover, the information on unintended harms (eg bone fractures, ketoacidosis, lower limb amputations) potentially associated with some SGLT2 inhibitors [2] [3] [4] [5] has been rapidly accumulating. The impact on healthcare resource utilization and costs has also not been fully evaluated in routine clinical care. Real-world data routinely generated in the course of healthcare delivery for millions of patients can fill these evidence gaps and inform regulatory and coverage decision-making, [6] [7] [8] as recently recommended by the 21st Century Cures Act and the Prescription Drug User Fee Act. 9, 10 The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) programme of studies aims to assess the comparative effectiveness, safety and impact on healthcare utilization of empagliflozin, based on real-world data from two commercial and Medicare databases in the United States The study will collect accumulating data on empagliflozin for a period of five years following the date of approval in the United States, 1 August 2014 through 30 September 2019. In the context of noninterventional studies of a newly available medication with prospectively accumulating real-world data, baseline information from the early stages can provide valuable insights regarding study validity and inform projections of exposure accrual over time and the resulting statistical power. 11, 12 These elements can be crucial to determine the level of confidence in future findings that may inform prompt decision-making with regard to diabetes treatment.
We sought to describe the rationale and study design of EMPRISE and, using the first year of data, to (a) assess the ability to overcome confounding and achieve high study validity by measuring baseline comparability of treatment groups in the study population; and (b) assess when adequate statistical power will be achieved using projected drug exposure accrual.
| ME THODS

| Data sources
This study includes data from two commercial US health insurance data sets (Optum Clinformatics and IBM MarketScan) with nationwide commercial coverage including some Medicare Advantage plans. As a third data source, we included fee-for-service Medicare, a US federal health insurance programme which provides health care to Americans aged 65 years or older and patients with disabilities.
The three data sources together cover about 200 million lives in the United States. For each insured individual, the three data sets contain demographic information, health plan enrolment status, longitudinal patient-level information on all reimbursed medical services, both inpatient and outpatient diagnoses and procedures along with pharmacy dispensing records, including information on medication start and refill, strength, quantity and days' supply. Both Optum and MarketScan are linked to laboratory test results provided by two national laboratory test provider chains. Through this linkage, results for outpatient laboratory tests are available for a subset of beneficiaries. All three data sources have been extensively used in pharmacoepidemiologic research. 13 All individual data were de-identified, the study was approved by the Brigham and Women's Hospital institutional review board, and signed data licence agreements were in place for all data sources. The study was registered at EnCEPP (EUPAS20677) and on ClinicalTrials. gov (NCT03363464).
| Study design
EMPRISE is a sequentially built new-user active-comparator cohort study that includes four planned interim analyses and one final analysis, using data from August 2014 to September 2019 ( Figure 1 ). For this manuscript, we focus on the first year of data.
New users of empagliflozin are 1:1 propensity score matched with initiators of dipeptidyl peptidase-4 (DPP-4) inhibitor. Cohort entry was the day of the first filled prescription of empagliflozin or a DPP-4 inhibitor, defined as no use of either SGLT2 inhibitors or DPP-4 inhibitors in the previous year among patients with at least a year of continuous enrolment prior to cohort entry. Study participants were patients aged 18 years or older with T2D, that is, with an inpatient or outpatient T2D diagnosis recorded during the year prior to drug initiation. Patients were excluded from the study if they had a diagnosis of type 1 diabetes, history of secondary or gestational diabetes, malignancy, end-stage renal disease, human immunodeficiency virus, organ transplant or a nursing home admission during the year prior to cohort entry (Table S1 and Figure S1 ).
This study design, based on sequentially built cohorts of new users, reduces confounding arising from differences between patients prescribed with the two treatments under investigation. 7, 12, 15 Furthermore, the study inclusion of new users of either a empagliflozin or a DPP-4 inhibitor, who had no use of either SGLT2 inhibitors or DPP-4 inhibitors during the year prior to cohort entry, reduces chances of time lag and immortal time biases that have plagued other real-world data studies of oral antidiabetics. 16, 17 DPP-4 inhibitors were chosen as the primary comparator group because they represent a comparable therapeutic alternative in a similar position in T2D treatment pathway, have similar glycemic efficacy and hypoglycaemia risk, and have demonstrated to be neutral on cardiovascular outcomes; [18] [19] [20] [21] [22] this enhances clinical equipoise across treatment groups and reduces confounding. 23, 24 Other comparators are considered for future analyses. As randomized controlled studies (RCTs) on SGLT2 inhibitors 1,2 and other antidiabetic agents 25, 26 are contributing new evidence that is prompting labelling changes 27, 28 and shaping clinical guidelines, 29 the EMPRISE protocol specifies for the use of additional comparison groups that over time may become more clinically meaningful to serve as contrasts for empagliflozin in particular population subgroups, such patients with cardiovascular or renal disease, that is, glucagon-like peptide-1 (GLP-1) receptor agonists. In anticipation of time-related changes in prescribing patterns, EMPRISE is designed to include tight 1:1 matching on calendar time.
Follow-up for study outcomes started on the day after the initiation of treatment and continued in an "as-treated" approach until discontinuation or switch to a drug in the comparator class, the occurrence of an outcome of interest, a nursing home admission, death, healthcare plan disenrolment or end of the study period (30 September 2015 for this first interim analysis), whichever came first.
We extended the exposure effect window until 30 days after the end of the last prescription's supply. In order to address more fully potential exposure misclassification, informative censoring and nature of the specific outcome assessed, 24 planned sensitivity analyses include the redefinition of the exposure risk window to 14 or 90 days after the end of the last prescription's days' supply interval, and the application of an intention-to-treat type approach, which will carry forward the initial exposure until the occurrence of a study event, healthcare plan disenrolment, admission to a nursing home or the end of the study period. 
| Study outcomes
1:1PS
these cardiovascular primary outcomes were 84% or higher. [30] [31] [32] [33] Detailed definitions for all study outcomes are available in Table S2 .
For the scope of this manuscript, we focused on HHF, defined as a hospitalization with a discharge diagnosis of heart failure in the primary position (positive predictive value [PPV] = 84%-100%), 33 the primary effectiveness outcome with the lowest expected incidence rate. This was to ensure that sufficient power was achieved for other primary outcomes. We also explored a broader definition of HHF, defined as a hospitalization with a discharge diagnosis of heart failure in any position (PPV = 79%-96%). 33
| Patient characteristics
Patient baseline characteristics were measured on the basis of enrolment information and claims during the 12 months before and including the date of cohort entry.
Covariates of interest included demographics, calendar time (in quarters and days), comorbidities, diabetes-specific complications, use of diabetes drugs, use of other medications, indicators of healthcare utilization as proxy for overall disease state, care intensity and surveillance, and laboratory test results, where available (Table 1; Appendix S1, Table S3 ). Patient characteristics were defined using (Table 1 ; Appendix S1, Table S3 ).
For a subset of about 45%-50% of patients in Optum and 5%-10%
in MarketScan, laboratory test results during the 12 months before cohort entry were available through linkage with two national laboratory test provider chains. In this subpopulation, laboratory test results were used to assess potential residual confounding by unmeasured factors not considered in the 1:1 propensity score matching on claims information only, a method that has demonstrated the success in confounding control in studies of patients with T2D. 23 The value closest to the cohort entry date (within the 1-year baseline period) was considered.
| Analysis
The statistical analysis plan for EMPRISE is reported in the Appendix S1, Summary of EMPRISE statistical analysis plan. Here, we focus on the analyses required to address the study validity.
To assess the ability of EMPRISE to overcome confounding, we cross-tabulated baseline patient characteristics by initiation of empagliflozin or DPP-4 inhibitors between August 2014 and September 2015 for each of the three cohorts. We evaluated frequencies and percentages for binary variables; and means (standard deviations) and medians (25th and 75th interquartile range) for continuous variables. Within each cohort, we estimated an exposure propensity score (PS) using a multivariable logistic regression predicting the initiation of empagliflozin vs. a DPP-4 inhibitor, conditional upon over 140 predefined baseline characteristics (Appendix S1: Table S3 ). 34 We 1:1 PS-matched patients using the nearest neighbour methodology with a maximum caliper of 0.01 of the PS. 35, 36 Postmatching covariate balance between empagliflozin and DPP-4 inhibitors was assessed by the calculation of two metrics for covariate balance:
standardized differences, with meaningful imbalances set at values >0.1, 37 and postmatching discrimination using the c-statistic from close to 0.5 if multivariate balance has been achieved. 38 We also assessed the postmatching balance achieved for selected laboratory test results, which have not been included in the PS model, including
HbA1c, creatinine and lipid levels.
We developed a model to predict the time when a statistical power of 80% could be achieved for the two HHF outcome definitions across the three EMPRISE data sources. For this purpose, we first used the power calculation formula for a two-group survival analysis to calculate the minimal number of events required to achieve sufficient power to reject the null hypothesis for each of the 
| RE SULTS
After the implementation of inclusion and exclusion criteria for the first interim analysis, we identified 7096 patients who initiated em- 
TA B L E 1 (Continued)
measured by the Claims-Based Frailty Index (CFI), 40 and had a lower general burden of comorbidities as measured by the combined comorbidity score 41 and by the prevalence of individual comorbidities at baseline, including ischaemic heart disease, stroke, heart failure, peripheral vascular disease, chronic kidney disease and diabetic nephropathy ( Table 1; Table S3 ); they also experienced fewer hospitalizations or emergency department visits during the year prior to treatment initiation. Conversely, empagliflozin initiators had higher prevalence of diabetic neuropathy or obesity, higher baseline use of insulin or glucagon-like peptide (GLP)-1 receptor agonists, higher number of antidiabetic medications at cohort entry, were less likely to be naïve new users, defined as not having used any diabetes treatment during the one year prior to cohort entry and were more likely to have had a visit with an endocrinologist prior to treatment initiation. After PS matching, all baseline patient characteristics were well balanced between initiators of empagliflozin and DPP-4 inhibitors with standardized differences smaller than 0.1 ( Table 1 ; Table S4 ).
For the subset of the population with laboratory values, available
test results for HbA1c and creatinine were well balanced after PS matching despite not having been components of the PS model.
Depending on the individual data source, the PS model c-statistic moved from 0.82-0.87 before matching to 0.54-0.59 after matching (Table S5 ).
| Population incidence of HHF, projected utilization trends and power considerations
After PS matching, the population mean (standard deviation) follow- Table 2) . For the broader HHF definition, the overall incidence rate was 14.78 per 1000 person-years (Table 2) .
Based on our power calculations, to detect a clinically meaningful effect on both HHF outcomes in line with the hazard ratio observed in the EMPA-REG OUTCOME trial (HR = 0.65), a minimum of 169 overall events among initiators of empagliflozin or DDP-4 inhibitors are needed to achieve 80% power for rejecting the null hypothesis for each of the two HHF outcomes at 5% significance level. Our model was based on the expected number of empagliflozin initiators at different years of EMPRISE (Table S7 ) and the observed rates of HHF outcomes or censoring events. It suggested that the number of accumulated events will exceed the threshold of 169 events by the end of year 3 for the more specific HHF definition, assuming ~37 000 accrued empagliflozin initiators, and by the end of year 2 for the broader definition, assuming ~17 000 accrued empagliflozin initiators. (Figure 4 ; Tables S8, S9 ). Because the periodic analyses in a prospective database study are not used to potentially end the study, to trigger regulatory action, to initiate follow-up studies or to prevent the publication or dissemination of the results from subsequent analyses, unlike a clinical trial, primary analyses will not be corrected for multiple looks over time via group sequential analysis.
Fully adjusted hazard ratios and 95% CIs will be estimated at each of the four interim analyses and the final analysis for all EMPRISE outcomes (Appendix S1, Summary of EMPRISE statistical analysis plan).
| D ISCUSS I ON
In a first interim analysis from the first year of EMPRISE, a new-user active-comparator cohort study, we demonstrated solid confounding control, as measured by the superior balance across treatment groups in a wide range of potential confounding factors and their proxies after propensity score matching and confirmed that we will reach adequate patient accrual rates for the achievement of powered interim analyses for all primary outcomes.
In the EMPA-REG OUTCOME trial, 1 42 and led to changes in major clinical guidelines with regard to diabetes treatment among patients with cardiovascular disease, 29, 43 which affects approximately one-third of all patients with T2D. 44 EMPRISE is an ongoing study programme on the comparative effectiveness, safety and healthcare utilization of empagliflozin based on real-world data among patients with T2D as treated in routine clinical care, which will collect accumulating data on empagliflozin for a period of five years following the date of approval in the United States, 1 August 2014 and will complement the findings from the EMPA-REG OUTCOME trial.
In the context of diabetes treatment, long-term outcome trials required by regulators 45, 46 to assess the cardiovascular safety of antidiabetic medications have yielded important information on both the benefits and risks associated with glucose-lowering agents. Nonetheless, RCTs may not be able to answer all ques- Over the past 20 years, tremendous advances have been made and new design and analytic standards are emerging to limit avoidable design flaws, for example, time-related biases, 16, 17 in which this monitoring programme incorporates to achieve high validity findings. [50] [51] [52] EMPRISE was designed to enhance clinical equipoise across treatment groups and minimize chances of confounding and time-related biases. 16, 17, 24, 53 Abbreviations: CI, confidence interval; HHF, Heart failure hospitalization; PS, propensity score; SD, standard deviation. a Defined as a hospitalization with a discharge diagnosis of heart failure in the primary position.
b In accordance with the data use agreement, we do not report information for frequency cells with <11 cases. These are noted as <11.
c Defined as a hospitalization with a discharge diagnosis of heart failure in any position.
bias. 55 However, the decreased risk of HHF observed in RCTs appeared equally early. Thus, the short follow-up observed in the current study is not expected to affect the assessment of HHF.
| CON CLUS ION
EMPRISE is a study programme on the comparative effectiveness, safety and healthcare utilization of empagliflozin in patients with T2D as treated in routine care. Baseline information from the first year of empagliflozin use provides evidence of solid confounding control and adequate exposure accrual with expected powered analyses for all primary outcomes by the end of year 3 of the study programme. These elements are crucial to inform the level of confidence in future findings. 
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